Mostrar el registro sencillo del ítem

Cholinesterase inhibitors for Alzheimer's disease: Multitargeting strategy based on anti-Alzheimer's drugs repositioning

dc.contributor.authorKabir M.T.
dc.contributor.authorUddin M.S.
dc.contributor.authorBegum M.M.
dc.contributor.authorThangapandiyan S.
dc.contributor.authorRahman M.S.
dc.contributor.authorAleya L.
dc.contributor.authorMathew B.
dc.contributor.authorAhmed M.
dc.contributor.authorBarreto G.E.
dc.contributor.authorAshraf G.M.
dc.date.accessioned2020-09-02T22:21:03Z
dc.date.available2020-09-02T22:21:03Z
dc.date.issued2019
dc.identifier10.2174/1381612825666191008103141
dc.identifier.citation25, 33, 3519-3535
dc.identifier.issn13816128
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4990
dc.descriptionIn the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improvement of AD. Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in AD because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEIs) have been continued to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs which are under development and their respective mechanisms of actions. © 2019 Bentham Science Publishers B.V.. All rights reserved.
dc.language.isoen
dc.publisherBentham Science Publishers
dc.subjectAcetylcholine
dc.subjectAcetylcholinesterase inhibitors
dc.subjectAlzheimer's disease
dc.subjectDonepezil
dc.subjectGalantamine
dc.subjectRivastigmine
dc.subjectTacrine
dc.subjectcholinesterase inhibitor
dc.subjectdonepezil
dc.subjectdonepezil derivative
dc.subjectgalantamine
dc.subjectgalantamine derivative
dc.subjectmemantine
dc.subjectplacebo
dc.subjectrivastigmine
dc.subjectrivastigmine derivative
dc.subjecttacrine
dc.subjecttacrine derivative
dc.subjecttheophylline
dc.subjectunclassified drug
dc.subjectcholinesterase inhibitor
dc.subjectdonepezil
dc.subjectgalantamine
dc.subjectrivastigmine
dc.subjecttacrine
dc.subjectabdominal cramp
dc.subjectabdominal pain
dc.subjectage
dc.subjectAlzheimer disease
dc.subjectanorexia
dc.subjectcholinergic system
dc.subjectdiarrhea
dc.subjectdizziness
dc.subjectdrug absorption
dc.subjectdrug blood level
dc.subjectdrug efficacy
dc.subjectdrug elimination
dc.subjectdrug half life
dc.subjectdrug mechanism
dc.subjectdrug structure
dc.subjectdyspepsia
dc.subjectfaintness
dc.subjectfatigue
dc.subjecthuman
dc.subjecthypertransaminasemia
dc.subjectinsomnia
dc.subjectliver toxicity
dc.subjectmuscle cramp
dc.subjectnausea
dc.subjectneurofibrillary tangle
dc.subjectplasma clearance
dc.subjectpriority journal
dc.subjectReview
dc.subjecttime to maximum plasma concentration
dc.subjectvomiting
dc.subjectdrug repositioning
dc.subjectAlzheimer Disease
dc.subjectCholinesterase Inhibitors
dc.subjectDonepezil
dc.subjectDrug Repositioning
dc.subjectGalantamine
dc.subjectHumans
dc.subjectRivastigmine
dc.subjectTacrine
dc.titleCholinesterase inhibitors for Alzheimer's disease: Multitargeting strategy based on anti-Alzheimer's drugs repositioning
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85074391012.pdf
Tamaño:
3.821Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem